Arthritis & Rheumatism

New test could predict arthritis drug failure in patients

A study of 311 patients by The University of Manchester has found that it may be possible to predict early which rheumatoid arthritis (RA) patients will fail to respond to the biologic drugs given to treat them. These findings ...

Arthritis & Rheumatism

Most part D plans cover at least one biologic DMARD

(HealthDay)—Although most Medicare Part D plans cover at least one biologic disease-modifying antirheumatic drug (DMARD), copayments are high, according to a study published in the June issue of Arthritis & Rheumatology.

Arthritis & Rheumatism

Gene discoveries could help rheumatoid arthritis treatment

(HealthDay)—Genetic variations may hold clues to rheumatoid arthritis—suggesting not only who will develop the painful condition, but also predicting its severity and even who might die from it, a new study says.

Arthritis & Rheumatism

Patients grapple with high cost of arthritis medications

The first national investigation of Medicare coverage of biologic disease modifying drugs (DMARDs) found that in starting a single biologic DMARD, patients face more than $2,700 in copayments each year before receiving relief ...

page 13 from 24